ArticleCureus2026
Impact of Drug-to-Drug Interactions on Patients With Advanced Cancer in Palliative Care Settings.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Family Medicine in Integrative Prevention and Management of Oncologic Diseases in Romania.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-to-drug interactions (DDIs) pose a significant challenge in managing elderly patients with chronic illnesses and polypharmacy. Similarly, patients with advanced malignancies often experience complex symptoms that necessitate the use of medications such as narcotics, tranquilizers, laxatives, antiemetics, and antipsychotics, drug classes known for their high risk of severe and potentially fatal interactions.
aimThe aim of this study is to assess the prevalence of DDIs, their categories and clinically significant adverse events among palliative care patients in Armed Forces Hospital, Southern Region, Saudi Arabia.
methodsWe conducted a prospective cross-sectional study involving palliative patients with advanced malignancies at the Palliative Medicine Department of Armed Forces Hospital, Southern Region, Saudi Arabia. The study evaluated the number of prescribed medications, the occurrence and categories of DDIs, their clinical significance, and the strategies used for management.
resultsWe enrolled 40 patients with advanced malignancies, with a mean age of 74 years (±14.5), ranging from 27 to 93 years, and nearly equal distribution of male patients (52.5%) and female patients (47.5%). DDIs were reported in 75% of the patients, with the majority (66.1%) classified as moderate in severity. Only 17.5% of patients experienced adverse effects related to DDIs, with sedation and confusion being the most frequently reported. Patients with DDIs also tended to have more severe symptoms, particularly pain, depression, and appetite loss. Polypharmacy, with a mean of 10.3 medications per patient, emerged as a key factor contributing to DDIs. Conclusion: DDIs are relatively common among palliative care patients, but clinically significant adverse events are infrequent. Given the small sample size and single-center design, findings should be interpreted with caution. Regular medication reviews and tailored prescribing may support safer, more patient-centered care at the end of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.